
- /
- Supported exchanges
- / US
- / RNA.NASDAQ
Avidity Biosciences Inc (RNA NASDAQ) stock market data APIs
Avidity Biosciences Inc Financial Data Overview
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Avidity Biosciences Inc data using free add-ons & libraries
Get Avidity Biosciences Inc Fundamental Data
Avidity Biosciences Inc Fundamental data includes:
- Net Revenue: 8 927 K
- EBITDA: -430 345 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.8803
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Avidity Biosciences Inc News

Wolfe Research initiates Avidity Biosciences stock with outperform rating
Wolfe Research initiated coverage on Avidity Biosciences (NASDAQ:RNA) with an outperform rating and a price target of $55.00 on Tuesday. Currently trading at $29.80, the stock sits well below analyst ...


Avidity Biosciences' SWOT analysis: innovative RNA tech targets rare disease stock potential
Avidity Biosciences, Inc. (NASDAQ:RNA) is a biotechnology company focused on developing innovative treatments for rare muscular diseases. The company’s proprietary Antibody Oligonucleotide Conjugate...

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc. (NASDAQ:RNA), with a Strong Buy ratin...

Raymond James bullish on biotech firms on favorable valuation
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic T...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.